For the future perspectives, the development of new therapeutic means to provide sufficient concentrations of IFN-β or α at tumor sites to achieve an antitumor effect is a key for the success of using an IFN-based therapy in cancer treatment. This evidence concerns the gene IFNB1 and neoplasm.